Breaking News Instant updates and real-time market news.

XLRN

Acceleron

$28.23

-0.81 (-2.79%)

16:32
06/12/17
06/12
16:32
06/12/17
16:32

Acceleron says DART Phase 2 study plus axitinib did not achieve primary endpoint

Acceleron Pharma announced that the DART Phase 2 study of dalantercept plus axitinib did not achieve its primary endpoint in advanced renal cell carcinoma. The primary efficacy endpoint of the study was to demonstrate a statistically significant increase in progression-free survival for treatment of dalantercept plus axitinib versus placebo plus axitinib in advanced RCC patients. The DART study enrolled 131 patients with advanced RCC. The efficacy data are based on the All-Treated Set which is defined as all randomized patients who received any study drug as of the database cutoff. In the ATS, 58 patients were randomized to dalantercept plus axitinib and 61 patients were randomized to placebo plus axitinib. "We designed a robust Phase 2 study to evaluate the efficacy of dalantercept in combination with anti-VEGF therapy in advanced renal cell carcinoma patients whose disease has progressed on prior anti-VEGF therapy. We are disappointed by the results given the need for new agents that improve outcomes for patients with advanced RCC. We would like to thank the patients, caregivers, investigators, and our team who made the DART study possible," said Habib Dable, President and Chief Executive Officer of Acceleron. "Based on the lack of efficacy, we are discontinuing the development of dalantercept. We remain focused on the development of luspatercept across multiple Phase 3 and Phase 2 studies and ACE-083 across two neuromuscular diseases, and will continue to pursue additional candidates in areas of high unmet medical need."

  • 20

    Jun

  • 22

    Jun

XLRN Acceleron
$28.23

-0.81 (-2.79%)

03/23/17
03/23/17
NO CHANGE

Outperform
Acceleron added to Alpha Generator List at FBR Capital
04/18/17
FBCO
04/18/17
INITIATION
Target $46
FBCO
Outperform
Acceleron assumed with an Outperform at Credit Suisse
Target $46.
05/17/17
GSCO
05/17/17
INITIATION
Target $20
GSCO
Sell
Acceleron initiated with a Sell at Goldman Sachs
Goldman analyst Terence Flynn initiated Acceleron with a Sell and a $20 price target saying Luspatercept is the key driver but most opportunities are already reflected in valuation. Flynn said Luspatercept Phase 3 data for two blood disorders isn't expected until mid-2018 and expects shares to be a relative underperformer given the lack of catalysts this year.
05/17/17
05/17/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. CoreSite Realty (COR) initiated with a Market Perform at Wells Fargo. 2. Acceleron (XLRN) initiated with a Sell at Goldman Sachs. 3. Cardinal Health (CAH) initiated with a Hold at Jefferies. 4. Concho Resources (CXO) assumed with an Overweight at Piper Jaffray. 5. Triangle Capital (TCAP) initiated with a Buy at Wunderlich. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

08:50
11/20/17
11/20
08:50
11/20/17
08:50
General news
U.S. equities are trading moderately firmer »

U.S. equities are trading…

ACOR

Acorda Therapeutics

$17.80

0.55 (3.19%)

08:49
11/20/17
11/20
08:49
11/20/17
08:49
Technical Analysis
Technical View: Acorda Therapeutics down on end of tozadenant development »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

KO

Coca-Cola

$45.71

-0.84 (-1.80%)

08:46
11/20/17
11/20
08:46
11/20/17
08:46
Recommendations
Coca-Cola analyst commentary  »

Coca-Cola investor day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$40.82

8.97 (28.16%)

08:45
11/20/17
11/20
08:45
11/20/17
08:45
Recommendations
Foot Locker analyst commentary  »

Foot Locker price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:45
11/20/17
11/20
08:45
11/20/17
08:45
General news
Oil Action: NYMEX crude »

Oil Action: NYMEX crude…

JNJ

Johnson & Johnson

$138.00

-0.87 (-0.63%)

08:43
11/20/17
11/20
08:43
11/20/17
08:43
Hot Stocks
EU extends license for Janssen's Zytiga plus prednisone »

Janssen-Cilag…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

LIVN

LivaNova

$84.32

0.04 (0.05%)

08:42
11/20/17
11/20
08:42
11/20/17
08:42
Recommendations
LivaNova analyst commentary  »

LivaNova received fair…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 01

    Dec

MNST

Monster Beverage

$62.17

0.17 (0.27%)

, KO

Coca-Cola

$45.71

-0.84 (-1.80%)

08:40
11/20/17
11/20
08:40
11/20/17
08:40
Downgrade
Monster Beverage, Coca-Cola rating change  »

Monster Beverage…

MNST

Monster Beverage

$62.17

0.17 (0.27%)

KO

Coca-Cola

$45.71

-0.84 (-1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NQ

NQ Mobile

$4.05

-0.05 (-1.22%)

08:40
11/20/17
11/20
08:40
11/20/17
08:40
Hot Stocks
NQ Mobile provides update on FL Mobile Divestment »

NQ Mobile provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENSG

Ensign Group

$23.77

0.22 (0.93%)

08:38
11/20/17
11/20
08:38
11/20/17
08:38
Recommendations
Ensign Group analyst commentary  »

Ensign Group price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRVL

Marvell

$20.29

0.03 (0.15%)

, CAVM

Cavium

$75.83

-0.47 (-0.62%)

08:37
11/20/17
11/20
08:37
11/20/17
08:37
Hot Stocks
Marvell: Cavium deal doesn't include divestitures, changes to Cavium's portfolio »

On the conference call…

MRVL

Marvell

$20.29

0.03 (0.15%)

CAVM

Cavium

$75.83

-0.47 (-0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 28

    Nov

  • 28

    Nov

BKS

Barnes & Noble

$7.45

0.35 (4.93%)

08:35
11/20/17
11/20
08:35
11/20/17
08:35
Hot Stocks
Barnes & Noble announces Black Friday weekend deals »

Barnes & Noble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

ARAY

Accuray

$4.80

-0.1 (-2.04%)

08:35
11/20/17
11/20
08:35
11/20/17
08:35
Technical Analysis
Technical View: Accuray rallies in pre-market »

The shares were last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNUS

Genius Brands

$2.88

0.02 (0.70%)

08:34
11/20/17
11/20
08:34
11/20/17
08:34
Hot Stocks
Genius Brands signs multiple content sales deals for children's programming »

Genius Brands expands the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIMT

Aimmune

$34.95

-0.33 (-0.94%)

08:34
11/20/17
11/20
08:34
11/20/17
08:34
Initiation
Aimmune initiated  »

Aimmune initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

WOR

Worthington

$40.24

0.03 (0.07%)

08:33
11/20/17
11/20
08:33
11/20/17
08:33
Hot Stocks
WAVE to sell EMEA, Pacific Rim units »

Worthington (WOR)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OTIV

On Track Innovations

$1.13

-0.01 (-0.88%)

08:32
11/20/17
11/20
08:32
11/20/17
08:32
Hot Stocks
On Track Innovations: UNO 6 selected by CityEV as cashless payment solution »

On Track Innovations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

MDSO

Medidata

$68.64

-0.85 (-1.22%)

08:32
11/20/17
11/20
08:32
11/20/17
08:32
Hot Stocks
Medidata, MEL MEDICAL announce multi-year Medidata eTMF agreement »

Medidata announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

PNTR

Pointer Telocation

$17.55

-0.2 (-1.13%)

08:30
11/20/17
11/20
08:30
11/20/17
08:30
Downgrade
Pointer Telocation rating change  »

Pointer Telocation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BZH

Beazer Homes

$20.50

0.04 (0.20%)

08:29
11/20/17
11/20
08:29
11/20/17
08:29
Recommendations
Beazer Homes analyst commentary  »

Beazer Homes price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:28
11/20/17
11/20
08:28
11/20/17
08:28
Conference/Events
The Board of Governors of the Federal Reserve System holds a closed meeting »

The Board of Governors of…

DG

Dollar General

$85.50

0.59 (0.69%)

, DLTR

Dollar Tree

$94.61

-0.02 (-0.02%)

08:28
11/20/17
11/20
08:28
11/20/17
08:28
Recommendations
Dollar General, Dollar Tree analyst commentary  »

Dollar General price…

DG

Dollar General

$85.50

0.59 (0.69%)

DLTR

Dollar Tree

$94.61

-0.02 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 07

    Dec

OMI

Owens & Minor

$19.14

0.23 (1.22%)

08:27
11/20/17
11/20
08:27
11/20/17
08:27
Recommendations
Owens & Minor analyst commentary  »

Owens & Minor price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIZZ

National Beverage

$102.23

0.32 (0.31%)

08:26
11/20/17
11/20
08:26
11/20/17
08:26
Upgrade
National Beverage rating change  »

National Beverage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$93.61

-0.86 (-0.91%)

08:25
11/20/17
11/20
08:25
11/20/17
08:25
Recommendations
AbbVie analyst commentary  »

AbbVie estimates raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.